HDAC9 and Parkinson disease: In light of the fact that the early stages of PD are characterised by rapid axonal degeneration [36,37], we set out to examine the effects of the class IIa HDAC inhibitor, MC1568 [38], on neurite growth and neuroprotection in three cell models [35].